Our Mission
Leveraging today's innovation for tomorrow's discovery through revolutionary macromolecular design.
Our Vision
To be a global leader in revolutionizing healthcare and diagnostics worldwide.
Our Values
Scientific integrity, patient-centered focus, and commitment to making breakthrough treatments.
Our Core Principles
These fundamental principles guide every decision we make and every solution we develop.
Scientific Excellence
We maintain the highest standards in research methodology and scientific rigor, ensuring every breakthrough is built on solid foundations.
Collaborative Innovation
Our multidisciplinary teams work together to tackle complex biological challenges through innovative approaches and shared expertise.
Quality Assurance
Every solution we develop undergoes rigorous testing and orthogonal validation.
Global Impact
We're committed to making our biotechnology solutions and improving health outcomes worldwide.
Leadership Team
Meet the visionary leaders driving innovation and excellence at Polymatika BioSolutions.
Dr. Trent C. Bjorndahl
Chief Executive Officer
Dr. Trent Bjorndahl is a researcher at the University of Alberta, specializing in enzyme biochemistry, NMR spectroscopy, structural and computational biology, metabolomics, proteomics, and analytical chemistry. With over 65 publications and more than 5,800 citations, Dr. Bjorndahl plays a pivotal role in developing advanced NMR-based metabolomic tools. He co-authored MetaboMiner, a widely used open-access software for semi-automated metabolite identification in 2D-NMR spectra, and was a key contributor to Bayesil, an automated NMR profiling platform. His research spans structural biology, small-molecule databases, and biomarker discovery through metabolomics, positioning him as a strong contributor to precision health and bioanalytical innovation. Dr. Bjorndahl holds Degrees in Pharmacy from the University of Saskatcehwan and a Ph.D. in Pharmaceutical Sciences from the University of Alberta.
Dr. David Wishart
Chief Scientific Officer
Dr. David S. Wishart is a Distinguished University Professor at the University of Alberta, with appointments in Biological Sciences, Computing Science, Pharmacy, and Laboratory Medicine. A leading figure in bioinformatics and metabolomics, Dr. Wishart has made transformative contributions to protein NMR spectroscopy and the creation of widely used databases such as the Human Metabolome Database (HMDB), DrugBank, and FooDB. He leads the Human Metabolome Project and founded The Metabolomics Innovation Centre (TMIC), Canada's national metabolomics facility. His research integrates structural biology, cheminformatics, and systems biology, with over 500 publications and 100,000 citations. Dr. Wishart is also a prolific innovator and entrepreneur, co-founding several biotech companies and developing more than 100 open-access tools. His work has helped define modern metabolomics and continues to shape precision health and biomedical research globally. Dr. Wishart holds a Degree in Physics from the University of Alberta and a Ph.D. in Molecular Biophysics from Yale.
Scientific Advisory Board
Distinguished experts providing strategic guidance and scientific oversight to our research programs.
Dr. Mark Berjanskii
Scientific Advisor
Dr. Mark Berjanskii is a Research Associate in the Department of Computing Science at the University of Alberta. His research spans protein structure determination, molecular flexibility prediction from NMR chemical shifts, model validation, and in-silico metabolite-protein docking. He's contributed to the development and implementation of several influential bioinformatic tools, including PROSESS, GeNMR, CS23D, ResProx, PPT-DB, and PREDITOR, advancing computational methods in NMR data analysis and protein dynamics. Mark holds a Ph.D. in Biochemistry from the University of Missouri-Columbia
Directors
Our experienced directors lead specialized teams across key areas of business development.
Tyler Wiens
Director
Tyler Wiens is a Senior Relationship Manager with expertise in delivering tailored financial solutions, risk management, and advisory services. Tyler plays a key role in understanding business operations, optimizing capital structures, and helping clients navigate market changes to achieve long-term prosperity. Tyler holds a BA in Agriculture from the University of Saskatchewan.
Robert E. Wanner
Director
Robert E. Wanner is a former Speaker of the Legislative Assembly of Alberta who served as the MLA for Medicine Hat. Before his election, Robert devoted over 35 years to municipal public service in Medicine Hat. He held senior roles in administration, social planning, police services, and housing including a position as Public Services Commissioner. Robert holds a MA degree in Social Welfare Policy from McMaster University and an MBA from the University of Calgary.
Our Story
Founded in 2025 by Dr. Bjorndahl, Polymatika Biosolutions emerged from novel artificial intelligence techniques that accelerated macromolecular design and revolutionized drug development.
We have developed a curated database of unique peptide fragments that allows for rapid, groundbreaking peptidomimetic compound design.
Peptidomimetics can be used for disease detection, monitoring, and treatment. They have applications as peptide-based drug conjugation systems as well as direct drug therapy.